Identification of unique nitric oxide-expressing hematopoietic stem cells and their special vascular niche
鉴定独特的表达一氧化氮的造血干细胞及其特殊的血管生态位
基本信息
- 批准号:9973669
- 负责人:
- 金额:$ 42.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-04-01 至 2020-08-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAgonistArteriesBiological AssayBloodBlood VesselsBone MarrowBone SurfaceCD 200CD34 geneCell physiologyCellsChimerismCiliaConflict (Psychology)DataDiscontinuous CapillaryEnsureExhibitsFailureGenerationsGeneticGoalsHematopoiesisHematopoietic Stem Cell TransplantationHematopoietic Stem Cell heterogeneityHematopoietic Stem Cell subsetsHematopoietic stem cellsHeterogeneityHistologicImageIndividualLocationMarrowMicroscopyMolecularMolecular ProfilingMusNitric OxideNitric Oxide SynthaseOsteoblastsPancytopeniaPatient-Focused OutcomesPopulationPublishingRadiationRadiation ProtectionRegulationReporterResearchRoleSLAM proteinSleeping BeautySoluble Guanylate CyclaseStressTestingTherapeuticTransplantationVeinsbaseclinical translationhematopoietic hierarchyhematopoietic stem cell nichehematopoietic stem cell quiescencehematopoietic stem cell self-renewalimproved outcomein vivoinsightirradiationmicroscopic imagingnovelnovel therapeutic interventionreceptorreconstitutionself-renewalsingle-cell RNA sequencingstem cell divisionstem cell populationtreatment strategytwo photon microscopytwo-photonyoung adult
项目摘要
Project Abstract Hematopoietic stem cells (HSCs) reside in the regulatory microenvironment within the bone
marrow (BM), termed the niche. Despite extensive research efforts made over the past decades, cellular
constituents and locations of the HSC niche have remained controversial. While early studies suggested that
HSCs are adjacent to osteoblasts on the bone surface, a growing amount of more recent evidence indicate that
HSCs are rather adjacent to sinusoidal vessels in the central marrow; some other showed HSCs are near BM
arteries. These conflicting observations may be explained by the heterogeneity of HSCs and the niche, as well
as the paucity of markers to identify HSC subsets in the histological analysis. This project focuses on proposing
most primitive HSCs among others, and their niche. The overall hypothesis to be tested is that nitric oxide (NO)
identifies unprecedented HSCs with distinctly high self-renewing and reconstituting potential. We further
hypothesize that these NO+ HSCs are regulated by unique transitional vessels which connect arteries to
sinusoidal vessels, while NO- HSCs with a relatively limited self-renewing potential are adjacent to sinusoidal
veins. This hypothesis is based on the following preliminary data. We showed that, within
CD150+CD48+cKit+Sca1+Lin- HSCs, there was a quiescent population (5-10%) with high expression levels of
NO and CD200 receptors (CD200R). These NO+CD200Rhigh HSCs exhibited high blood reconstituting potential
which was further increased by serial transplant, while NO- HSCs' reconstituting potential was relatively limited
and abolished by serial transplant. This observation suggest NO+ HSCs possess a distinctly high self-renewal
and reconstituting potential. Moreover, NO+ HSCs were adjacent to transitional vessels, while NO- HSCs were
adjacent to sinusoids which did not express cilia or CD200. To further bring mechanistic insights into NO+ HSCs
and their niche and to promote clinical translation of our basic findings, we will pursue the following aims. In Aim
1, we will seek to characterize NO+ HSCs' self-renewal, reconstituting potential and molecular features, and
elucidate their intrinsic regulatory mechanisms of NO+ HSCs, by using the combination of single cell RNA
sequencing, transplantation assay, genetic deletion, and in vivo microscopy tracking of symmetric or asymmetric
division of photolabeled individual HSCs. In Aim 2, we will elucidate NO+ HSCs' locations and extrinsic regulatory
mechanisms. We will validate localization of NO+ HSCs to transitional vessels by performing deep whole-mount
2-photon BM imaging of novel HSC-reporter mice. We will further elucidate roles of transitional vessels' CD200
and cilia in HSC regulation and protection from radiation stress. We will finally investigate therapeutic potential
of CD200R agonist treatment to mitigate post-irradiation hematopoiesis failure. Completion of the project may
address the controversy about the niche location by proposing unprecedented primitive HSCs and its niche.
Successful studies will further identify cilia-CD200/CD200R-NO axis as new HSC regulators, leading to novel
treatments for hematopoiesis failure.
造血干细胞(HSCs)存在于骨内的调控微环境中
骨髓(BM),称为niche。尽管在过去几十年中进行了广泛的研究,
HSC利基的组成和位置仍然存在争议。虽然早期的研究表明,
HSC与骨表面的成骨细胞相邻,越来越多的最新证据表明,
在中央骨髓中,HSC与窦状血管相邻;其他一些研究显示,HSC与BM相邻
动脉这些相互矛盾的观察结果可以解释的异质性HSC和生态位,以及
因为缺乏在组织学分析中识别HSC亚群的标记物。该项目旨在提出
最原始的HSC和它们的生态位。待检验的总体假设是一氧化氮(NO)
识别出具有明显高自我更新和重建潜力的前所未有的HSC。我们进一步
假设这些NO+ HSC由连接动脉的独特过渡血管调节,
窦状血管,而具有相对有限的自我更新潜力的NO-HSC邻近窦状血管,
静脉这一假设基于以下初步数据。我们发现,
CD 150 + CD 48 +cKit+ Sca 1 +Lin-HSC中,存在具有高表达水平的CD 150 + CD 48 +cKit+ Sca 1 +Lin-HSC的静止群体(5-10%)。
NO和CD 200受体(CD 200 R)。这些NO+ CD 200 Rhigh HSC具有较高的血液重建能力
连续移植可进一步提高NO-HSC的再生能力,但NO-HSC的再生能力相对有限
并通过连续移植消除。这一观察结果表明NO+ HSC具有明显的高自我更新能力
和重建潜力。此外,NO+ HSC与移行血管相邻,而NO-HSC与移行血管相邻。
邻近窦状隙,不表达纤毛或CD 200。进一步深入了解NO+ HSC的机制
和他们的利基,并促进我们的基本研究结果的临床转化,我们将追求以下目标。在Aim中
1、我们将寻求表征NO+ HSC的自我更新、重建潜力和分子特征,
通过使用单细胞RNA的组合,阐明NO+ HSC的内在调节机制,
测序、移植测定、遗传缺失和体内显微镜追踪对称或不对称的
光标记的单个HSC的分裂。在目标2中,我们将阐明NO+ HSC的定位和外源性调控,
机制等我们将通过进行深整体包埋,
2-新型HSC报告小鼠的光子BM成像。我们将进一步阐明移行血管CD 200的作用,
和纤毛在HSC调节和辐射应激保护中的作用。我们将最终研究治疗潜力
CD 200 R激动剂治疗以减轻辐射后造血衰竭。该项目的完成可能
通过提出前所未有的原始HSC及其生态位来解决关于生态位位置的争议。
成功的研究将进一步确定纤毛-CD 200/CD 200 R-NO轴作为新的HSC调节因子,从而导致新的HSC调节因子。
造血衰竭的治疗方法
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joji Fujisaki其他文献
Joji Fujisaki的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joji Fujisaki', 18)}}的其他基金
Identification of unique nitric oxide-expressing hematopoietic stem cells and their special vascular niche
鉴定独特的表达一氧化氮的造血干细胞及其特殊的血管生态位
- 批准号:
10561727 - 财政年份:2021
- 资助金额:
$ 42.55万 - 项目类别:
Identification of unique nitric oxide-expressing hematopoietic stem cells and their special vascular niche
鉴定独特的表达一氧化氮的造血干细胞及其特殊的血管生态位
- 批准号:
10331423 - 财政年份:2021
- 资助金额:
$ 42.55万 - 项目类别:
Privileged and primitive hematopoietic stem cells, niches, and regulatory T cells
特权和原始造血干细胞、生态位和调节性 T 细胞
- 批准号:
10531890 - 财政年份:2021
- 资助金额:
$ 42.55万 - 项目类别:
Privileged and primitive hematopoietic stem cells, niches, and regulatory T cells
特权和原始造血干细胞、生态位和调节性 T 细胞
- 批准号:
10364110 - 财政年份:2021
- 资助金额:
$ 42.55万 - 项目类别:
Identification of unique nitric oxide-expressing hematopoietic stem cells and their special vascular niche
鉴定独特的表达一氧化氮的造血干细胞及其特殊的血管生态位
- 批准号:
10398258 - 财政年份:2021
- 资助金额:
$ 42.55万 - 项目类别:
Roles and therapeutic potential of CD150high niche-associated regulatory T cells in bone marrow injury and engraftment
CD150高生态位相关调节性T细胞在骨髓损伤和植入中的作用和治疗潜力
- 批准号:
10322010 - 财政年份:2019
- 资助金额:
$ 42.55万 - 项目类别:
Roles and therapeutic potential of CD150high niche-associated regulatory T cells in bone marrow injury and engraftment
CD150高生态位相关调节性T细胞在骨髓损伤和植入中的作用和治疗潜力
- 批准号:
10163898 - 财政年份:2019
- 资助金额:
$ 42.55万 - 项目类别:
Roles and therapeutic potential of CD150high niche-associated regulatory T cells in bone marrow injury and engraftment
CD150高生态位相关调节性T细胞在骨髓损伤和植入中的作用和治疗潜力
- 批准号:
10456272 - 财政年份:2019
- 资助金额:
$ 42.55万 - 项目类别:
Immune privilege of the hematopoieitic stem cell niche
造血干细胞生态位的免疫特权
- 批准号:
10322011 - 财政年份:2016
- 资助金额:
$ 42.55万 - 项目类别:
Immune privilege of the hematopoieitic stem cell niche
造血干细胞生态位的免疫特权
- 批准号:
9895853 - 财政年份:2016
- 资助金额:
$ 42.55万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 42.55万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 42.55万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 42.55万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 42.55万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 42.55万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 42.55万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 42.55万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 42.55万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 42.55万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 42.55万 - 项目类别:
Grant-in-Aid for Scientific Research (C)